Rani Therapeutics Secures $1.085B Collaboration, $60.3M Private Placement, Extends Runway to Q4 2027
RANI has more than doubled off its 52-week low of $0.387 on elevated volume (2.3× avg).
Summary
Rani Therapeutics announced a transformative collaboration worth up to $1.085 billion with Chugai Pharmaceutical, alongside a $60.3 million oversubscribed private placement, significantly strengthening its financial position and extending its cash runway into late 2027.
Key Events · Financing and Capital Events · RANI
-
Major Collaboration Agreement
Rani Therapeutics entered into a Collaboration and License Agreement with Chugai Pharmaceutical Co. for up to $1.085 billion to develop an oral therapy, with an option to expand rights to five additional drug targets.
-
Significant Private Placement
The company completed a $60.3 million oversubscribed private placement in October 2025, led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus.
-
Debt Obligations Fully Satisfied
Rani Therapeutics repaid all outstanding debt to Avenue in December 2025, including a remaining principal balance of $6.2 million, eliminating all outstanding debt obligations as of December 31, 2025.
-
Extended Cash Runway
With the new capital and expected milestone payments, Rani Therapeutics expects its cash, cash equivalents, and marketable securities to be sufficient to fund operations into the fourth quarter of 2027.
Analysis · RANI · Life Sciences
This 8-K details a highly positive corporate update for Rani Therapeutics, highlighted by a substantial collaboration agreement with Chugai Pharmaceutical, potentially valued at up to $1.085 billion. Concurrently, the company completed an oversubscribed $60.3 million private placement with leading biotech investors, which, combined with the elimination of all outstanding debt, has dramatically improved its balance sheet. These financing activities extend Rani's cash runway into the fourth quarter of 2027, significantly de-risking its operations and providing capital for continued development. The progress in preclinical data for oral semaglutide and RT-114, along with the initiation of a Phase 1 study for RT-114, further validates the RaniPill® platform and its potential in high-value therapeutic areas. This comprehensive update signals strong institutional confidence and a strengthened path forward for the company.
At the time of this filing, RANI was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $131.2M. The 52-week trading range was $0.39 to $3.87. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.